Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine.
The patient was 32-year-old man, who received olanzapine for schizophrenia and developed polyuria and thirst without drinking soft-drinks after 4 months. Five months after the initiation of treatment, he developed diabetic ketoacidosis (blood glucose: 490 mg/dL, HbA1c: 15.5%). He was diagnosed with type 1 diabetes (glutamic acid decarboxylase (GAD)-Ab: 5.6 U/mL, IA-2 Ab: 5.9 U/mL, fasting C-peptide: 0.12 ng/mL) and was put on intensive insulin therapy. At four months after the onset of 1A diabetes, he experienced a honeymoon phase that was sustained until the 40th month of treatment. We hypothesize that the administration of olanzapine to a patient with pre-type 1A diabetes induced marked hyperglycemia and accelerated the onset of type 1A diabetes.
Department of Internal Medicine, Division of Endocrinology and Metabolism, Showa-University Fujigaoka Hospital, Japan.
Kenji
K
Iwaku
Fumiko
F
Otuka
Matsuo
M
Taniyama
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects*; D001786:Blood Glucose; D003922:Diabetes Mellitus, Type 1 / Q000175:diagnosis* / Q000503:physiopathology; D016883:Diabetic Ketoacidosis / Q000139:chemically induced / Q000188:drug therapy; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced* / Q000188:drug therapy; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D000077152:Olanzapine; D011236:Prediabetic State / Q000150:complications / Q000175:diagnosis*; D012559:Schizophrenia / Q000188:drug therapy
D014150:Antipsychotic Agents; D001786:Blood Glucose; D007328:Insulin; D001569:Benzodiazepines; D000077152:Olanzapine